(15352506), C. A., (15352509), A. B., (15352512), R. S., (15352515), M. G., (15352518), A. C., (15086287), D. R., . . . (15352566), C. C. (2025). Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
توثيق أسلوب شيكاغو (الطبعة السابعة عشر)(15352506), Carlotta Antoniotti, et al. Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer. 2025.
توثيق جمعية اللغة المعاصرة MLA (الإصدار التاسع)(15352506), Carlotta Antoniotti, et al. Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer. 2025.